Abbvie stock forecast 2025 regulatory outlook in the AbbVie stock

Regulatory outlook in the AbbVie stock forecast 2025 points toward favorable FDA decisions on neurology drug candidates, enhancing sector leadership. These catalysts could help ABBV outperform broader pharma indices. Swaps are discounting a 1% chance for a -25 bp rate cut by the ECB at its next policy meeting on October 30. We have seen $512,569 of award payments to $ABBV over the last year. AbbVie stock forecast 2025 indicates steady long-term upside potential, with analysts projecting earnings per share growth driven by strong revenue from immunology drugs like Skyrizi and Rinvoq. Market consensus points to a possible price range of $185–$205, assuming current pipeline progress continues without regulatory setbacks.